Joseph Kut
Psychiatry · Arlington Heights, ILNPI 1750365490
Payments from drug & device makers
Across 142 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$548
- Takeda Pharmaceuticals U.S.A., Inc.$310
- AbbVie$237
- Otsuka America Pharmaceutical, Inc.$218
- Neurocrine Biosciences, Inc.$204
- Shire North American Group Inc$156
- plus $597 from 11 others
What the payments were for
- Food & beverage$2,22298%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 34 | $548 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $310 |
| AbbVie(2 entities) | 17 | $237 |
| Otsuka America Pharmaceutical, Inc. | 12 | $218 |
| Neurocrine Biosciences, Inc. | 12 | $204 |
| Shire North American Group Inc | 10 | $156 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $137 |
| Johnson & Johnson | 5 | $96 |
| Adlon Therapeutics L.p. | 6 | $95 |
| Alkermes, Inc. | 4 | $94 |
| Vertical Pharmaceuticals, LLC | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Bausch Health US, LLC | 2 | $28 |
| Neos Therapeutics, LP | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Indivior Inc. | 1 | $12 |
How this compares
$2,269 in reported general payments places this provider in the 80th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $96,543 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,275 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $6,058 |
| Eszopiclone | 19 | $2,189 |
| Olanzapine | 74 | $2,155 |
| Lurasidone Hcl | 15 | $2,097 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 59 | $1,915 |
| Clozapine | 12 | $1,787 |
| Phenelzine Sulfate | 11 | $1,607 |
| Duloxetine Hcl | 67 | $1,573 |
| Clorazepate Dipotassium | 24 | $1,490 |
| Alprazolam OdtAlprazolam | 11 | $1,432 |
| Bupropion XlBupropion Hcl | 60 | $1,314 |
| Aripiprazole | 73 | $1,265 |
| Clonazepam | 102 | $1,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $204 | $96,54312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $310 | $12,33427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Arlington Heights
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.